Volume 18, Issue 59 (4-2024)
MLJ 2024, 18(59): 487-501 |
Back to browse issues page
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Montazeri M, Shokrian Amir H. Civil Responsibility of Using Artificial Intelligence in Pharmaceuticals. MLJ 2024; 18 (59) :487-501
URL: http://ijmedicallaw.ir/article-1-1870-en.html
URL: http://ijmedicallaw.ir/article-1-1870-en.html
1- Department of Law, Takestan Branch, Islamic Azad University, Takestan, Iran.
2- Department of Jurisprudence and Fundamentals of Islamic Law, Faculty of Theology and Islamic Sciences, Mazandaran University, Mazandaran, Iran.
2- Department of Jurisprudence and Fundamentals of Islamic Law, Faculty of Theology and Islamic Sciences, Mazandaran University, Mazandaran, Iran.
Abstract:
Background and Aim: Civil liability in the use of artificial intelligence (AI) in pharmaceuticals is a complex and important issue that is related to various rights and obligations in the field of manufacturing and distributing drugs. The present research, studies the civil responsibility of using artificial intelligence in pharmaceuticals.
Method: This research is of a theoretical type and the research method is descriptive-analytical and the method of collecting information is library-based and was done by referring to documents, books and articles.
Ethical Considerations: In this research, the principles of trustworthiness, honesty, neutrality and originality of the work have been respected.
Results: Artificial intelligence in pharmaceuticals may be used to analyze data and predict the effects of drugs. If the input data is incorrect or incomplete and results in erroneous results, it is possible that liability may arise for drug manufacturers, algorithm developers, or regulatory bodies. If an AI system mistakenly prescribes a drug and harms a patient as a result, software developers or doctors may be held liable.
Conclusion: Deficiencies in monitoring can lead to liability for regulatory bodies. In many cases, companies enter into collaboration with AI technologies through agreements. The terms of these agreements can help determine responsibilities and obligations. The use of AI in pharmaceuticals also raises various ethical issues, including patient data privacy and fairness in treatment. Finally, given the rapid growth of AI technologies, there is a need for independent regulatory and legal frameworks to clearly define responsibilities and protect the rights of patients and consumers.
Please cite this article as:
Montazeri M, Shokrian Amiri H. Civil Responsibility of Using Artificial Intelligence in Pharmaceuticals. Medical Law Journal. 2024; 18: e34.
Method: This research is of a theoretical type and the research method is descriptive-analytical and the method of collecting information is library-based and was done by referring to documents, books and articles.
Ethical Considerations: In this research, the principles of trustworthiness, honesty, neutrality and originality of the work have been respected.
Results: Artificial intelligence in pharmaceuticals may be used to analyze data and predict the effects of drugs. If the input data is incorrect or incomplete and results in erroneous results, it is possible that liability may arise for drug manufacturers, algorithm developers, or regulatory bodies. If an AI system mistakenly prescribes a drug and harms a patient as a result, software developers or doctors may be held liable.
Conclusion: Deficiencies in monitoring can lead to liability for regulatory bodies. In many cases, companies enter into collaboration with AI technologies through agreements. The terms of these agreements can help determine responsibilities and obligations. The use of AI in pharmaceuticals also raises various ethical issues, including patient data privacy and fairness in treatment. Finally, given the rapid growth of AI technologies, there is a need for independent regulatory and legal frameworks to clearly define responsibilities and protect the rights of patients and consumers.
Please cite this article as:
Montazeri M, Shokrian Amiri H. Civil Responsibility of Using Artificial Intelligence in Pharmaceuticals. Medical Law Journal. 2024; 18: e34.
Type of Study: Original Article |
Received: 2024/07/28 | Accepted: 2024/11/9
Received: 2024/07/28 | Accepted: 2024/11/9
Send email to the article author
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
